https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204856
Jan 03, 2024 - We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
zc:-6303957344621396969
0
https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196
Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zc:-4643956653710555069
0
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
zc:5632938074738624243
0
https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211548
Jan 17, 2024 - Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
zc:-6600895409325080549
0
https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
zc:-5634115568131083711
0
https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212290
Jan 18, 2024 - Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
zc:6966983953777213566
0
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
zc:5586419536017940380
0
https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118
Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
zc:4058698359472848859
0
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
zc:6104452854925000797
0
https://www.zacks.com/stock/news/2223576/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2223576
Feb 08, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
zc:-4879637129966387390
0